Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

October 19, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Abrocitinib 200 MG Oral Tablet

Abrocitinib

DRUG

Ritlecitinib

Ritlecitinib

DRUG

Placebo

Placebo for Abrocitinib or Ritlecitinib

Trial Locations (30)

2065

Royal North Shore Hospital, Saint Leonards

3050

3. Royal Melbourne Hospital, Parkville

3052

The Royal Children's Hospital - Melbourne, Melbourne

4101

Queensland Children's Hospital, South Brisbane

5006

Women and Children's Hospital-Adelaide, Adelaide

6009

Perth Children's Hospital, Nedlands

10032

Columbia University-Naomi Berrie Diabetes Center, New York

13210

Joslin Center at SUNY Upsate, Syracuse

14203

UBMD Pediatrics, Buffalo

15224

University of Pittsburgh, Pittsburgh

30322

Emory Children's Center, Atlanta

32610

University of Florida, Gainesville

33136

University of Miami, Miami

33612

University of South Florida Diabetes Center, Tampa

37232

Vanderbilt University Medical Center, Nashville

40202

University of Louisville Pediatric Endocrinology, Louisville

46202

Indiana University, Indianapolis

55455

University of Minnesota, Minneapolis

60637

University of Chicago, Chicago

64111

The Children's Mercy Hospital, Kansas City

75390

University of Texas Southwestern, Dallas

80045

Barbara Davis Center at University of Colorado Anschutz Medical Campus, Aurora

84112

University of Utah, Salt Lake City

92868

Children's Hospital Orange County, Orange

94143

University of California- San Francisco, San Francisco

94304

Stanford University, Palo Alto

98101

Benaroya Research Institute, Seattle

06511

Yale University School of Medicine, New Haven

02215

Joslin Diabetes Center, Boston

M5G1X8

Hospital for Sick Children, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH